OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%
#1
OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%, Successfully Completes EvinceMed Acquisition
  • Revenue Up 22% to $13.7 million on increased average revenue per top 20 pharmaceutical manufacturer client
  • Traction with top 20 pharmaceutical manufacturers continues to advance and drive growth
  • Cash flow positive from operations of $4.1 million    
ROCHESTER, Mich., May 04, 2022 (GLOBE NEWSWIRE) --  OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2022. Quarterly comparisons are to the same year-ago period.

Read more here
Reply


Forum Jump: